Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DR26FMDW7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $59,575
Award facts
- Contract value 100% obligated
- $59,574.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $59,574.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on November 13, 2025, with an ultimate completion date of November 14, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and executed under the company's recently awarded Indefinite Delivery Contract within the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative.
This delivery order represents one of numerous pharmaceutical supply commitments issued to DMS Pharmaceutical Group under its single-award indefinite delivery contract, which carries a $499.999 billion ceiling value and extends through December 31, 2036. The PPV-G GEN V program, a $30.3 billion acquisition strategy, establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply comprehensive pharmaceutical products—including branded and generic prescription medications, biologics, and medical consumables—to support Department of Defense healthcare operations globally. The contractor's established performance across multiple therapeutic categories and product lines positions it as a critical supplier within the federal military medical pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FMDW7?
SPE2DR26FMDW7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FMDW7 worth?
The government has obligated $59,575 on SPE2DR26FMDW7.
Is contract SPE2DR26FMDW7 an order under another contract?
Yes. SPE2DR26FMDW7 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDW7 competed?
The extent of competition for SPE2DR26FMDW7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award